The exclusive worldwide agreement adds an anti-C5a antibody for ANCA-associated vasculitis to Mirador’s immunology pipeline, with Phase 1 planned by year-end 2026 and Phase 2 in the first half of 2027.
verifying reliability
No specialized terms available for this topic.